Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00111696
Status:
COMPLETED
Last Update Posted:
2012-03-14
First Post:
2005-05-24
Brief Title:
Study of the Tumor Saturation and Biological Activity of MEDI-522 Abergrin in Patients With Advanced Malignant Melanoma
Sponsor:
MedImmune LLC
Organization:
MedImmune LLC
Study Overview
Official Title:
Phase I Study of the Tumor Saturation and Biological Activity of MEDI-522 Abergrin a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin in Patients With Advanced Malignant Melanoma
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UPCI 05-025 | OTHER | MedImmune - placeholder | None |
| CRRI 0305014 | OTHER | None | None |